JCR Pharmaceuticals Co., Ltd.
Clinical trials sponsored by JCR Pharmaceuticals Co., Ltd., explained in plain language.
A Japanese pharmaceutical company specializing in rare disease therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new enzyme therapy tame MPS II over time? Results expected Dec 2026 (estimated)
-
New hope for kids with rare sanfilippo syndrome? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called JR-446 in 10 children with mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B), a rare genetic disease that affects the brain and body. The drug is given through an IV and aims to be safe and possibly help manage the conditi…
Phase 1/2 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:37 UTC
-
Rare disease study seeks clues for future treatments
Knowledge-focused Recruiting nowThis study tracks the natural course of fucosidosis, a rare genetic disorder, in up to 57 people. It collects medical history and ongoing health data without giving any experimental treatment. The goal is to better understand the disease and help design future therapies.
Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC